Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDway: modified tafasitamab IV dosing with lenalidomide in relapsed or refractory DLBCL
2023-507993-42-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Mar 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab and elranatamab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), sponsored by Incyte. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Planned start Mar 2022; status: authorised.
02
Drugs
tafasitamabelranatamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Beyond the preview
Go deeper on 2023-507993-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507993-42-00.